Patents by Inventor Shiro Shibayama
Shiro Shibayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250145719Abstract: The present application provides an immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.Type: ApplicationFiled: January 10, 2025Publication date: May 8, 2025Applicants: Ono Pharmaceutical Co., Ltd., Tokushima UniversityInventors: Taku OKAZAKI, Daisuke Sugiura, Takeo Maeda, Shiro Shibayama
-
Patent number: 12234289Abstract: An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.Type: GrantFiled: December 6, 2019Date of Patent: February 25, 2025Assignees: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITYInventors: Taku Okazaki, Daisuke Sugiura, Takeo Maeda, Shiro Shibayama
-
Patent number: 12091461Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: GrantFiled: July 2, 2021Date of Patent: September 17, 2024Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan de Kruif, Pieter Fokko van Loo, Rinse Klooster
-
Publication number: 20240287187Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: ApplicationFiled: April 30, 2024Publication date: August 29, 2024Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan DE Kruif, Pieter Fokko van Loo, Rinse Klooster
-
Patent number: 11919932Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: January 3, 2023Date of Patent: March 5, 2024Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Publication number: 20230256054Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer includes administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.Type: ApplicationFiled: March 14, 2023Publication date: August 17, 2023Applicant: ONO PHRMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Hiroshi ARIMA, Takuya SIMBO
-
Publication number: 20230220022Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: January 3, 2023Publication date: July 13, 2023Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Patent number: 11638744Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.Type: GrantFiled: September 2, 2016Date of Patent: May 2, 2023Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Hiroshi Arima, Takuya Simbo
-
Patent number: 11572393Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: March 7, 2019Date of Patent: February 7, 2023Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Publication number: 20220372148Abstract: An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.Type: ApplicationFiled: July 3, 2020Publication date: November 24, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO
-
Publication number: 20220332825Abstract: A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.Type: ApplicationFiled: August 7, 2020Publication date: October 20, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA
-
Publication number: 20220281977Abstract: A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.Type: ApplicationFiled: July 29, 2020Publication date: September 8, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER
-
Publication number: 20220227887Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.Type: ApplicationFiled: June 10, 2020Publication date: July 21, 2022Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITYInventors: Taku OKAZAKI, Daisuke SUGIURA, II-mi OKAZAKI, Shiro SHIBAYAMA
-
Publication number: 20220185885Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.Type: ApplicationFiled: April 3, 2020Publication date: June 16, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER, Robertus Cornelis ROOVERS
-
Publication number: 20220025051Abstract: An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.Type: ApplicationFiled: December 6, 2019Publication date: January 27, 2022Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITYInventors: Taku OKAZAKI, Daisuke SUGIURA, Takeo MAEDA, Shiro SHIBAYAMA
-
Publication number: 20210332134Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: ApplicationFiled: July 2, 2021Publication date: October 28, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
-
Patent number: 11091550Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: GrantFiled: February 8, 2019Date of Patent: August 17, 2021Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan de Kruif, Pieter Fokko van Loo, Rinse Klooster
-
Publication number: 20210214441Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: ApplicationFiled: February 8, 2019Publication date: July 15, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
-
Publication number: 20200407408Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: March 7, 2019Publication date: December 31, 2020Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Publication number: 20200317783Abstract: A prophylactic, symptom progress-suppressive, recurrence-suppressive and/or therapeutic agent for autoimmune disease or graft-versus-host disease, comprising a PD-1/CD19 bispecific antibody or antibody fragment thereof having a first arm capable of specifically binding to PD-1 and a second arm capable of specifically binding to CD19, as an active ingredient. The PD-1/CD19 bispecific antibody exhibits suppressive effect on proliferation of activated B cells and suppressive effect on production of immunoglobulin, and also has an effect of suppressing production of cytokine from memory T cells.Type: ApplicationFiled: October 5, 2018Publication date: October 8, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA